Biotest Aktiengesellschaft (ETR: BIO)
Germany
· Delayed Price · Currency is EUR | Market Cap | 1.33B |
| Revenue (ttm) | 707.00M |
| Net Income (ttm) | 68.50M |
| Shares Out | n/a |
| EPS (ttm) | 1.73 |
| PE Ratio | 19.41 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 116 |
| Open | 41.00 |
| Previous Close | 41.40 |
| Day's Range | 41.00 - 41.40 |
| 52-Week Range | 40.40 - 43.00 |
| Beta | 0.24 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Mar 28, 2025 |
About ETR: BIO
Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. It operates through three segments: European Union, Rest of the World, and Stateless. The company specializes primarily in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company’s produ... [Read more]
Financial Performance
Financial StatementsNews
EQS-News: Minister of Economic Affairs Mansoori and Lord Mayor Benz visit Biotest's plasma center in Darmstadt and call for plasma donations
EQS-News: Biotest AG / Key word(s): Miscellaneous Minister of Economic Affairs Mansoori and Lord Mayor Benz visit Biotest's plasma center in Darmstadt and call for plasma donations 15.11.2024 / 09:00 ...
Biotest Boosts Revenue by 4.5% to €523M in First 9 Months!
Biotest has reported a promising financial performance for the first nine months of 2024, with revenues climbing by 4.5% to €523 million. This growth is fueled by strong product sales and strategic de...
EQS-News: Biotest increases revenues in the first 9 months by 4.5% to Euro 523 million
EQS-News: Biotest AG / Key word(s): 9 Month figures Biotest increases revenues in the first 9 months by 4.5% to Euro 523 million 14.11.2024 / 10:14 CET/CEST The issuer is solely responsible for the co...
Biotest AG: Revenue & Cash Flow Forecast Cut, EBIT Guidance Steady
Biotest AG has adjusted its 2024 financial outlook, predicting modest revenue growth and revised ROCE and cash flow expectations, while maintaining steady EBIT projections. Jetzt den vollständigen Art...
EQS-Adhoc: Biotest AG: Biotest corrects forecast for revenue, cash flow and ROCE – EBIT guidance unchanged
EQS-Ad-hoc: Biotest AG / Key word(s): Change in Forecast Biotest AG: Biotest corrects forecast for revenue, cash flow and ROCE – EBIT guidance unchanged 14-Nov-2024 / 08:56 CET/CEST Disclosure of an i...
Kedrion and Biotest complete long-term Exclusive Distribution Agreement for Yimmugo® in the US
Contractual terms finalized and definitive agreement between Kedrion and Biotest signed based on framework agreed in July Distribution agreement requires Biotest to supply and Kedrion to purchase mini...
EQS-News: Strategic agreement signed for distribution of Yimmugo in the United States based on the framework established in July
EQS-News: Biotest AG / Key word(s): Market Launch Strategic agreement signed for distribution of Yimmugo in the United States based on the framework established in July 02.10.2024 / 14:00 CET/CEST The...
EQS-News: Change in the Chief Financial Officer at Biotest AG
EQS-News: Biotest AG / Key word(s): Personnel Change in the Chief Financial Officer at Biotest AG 12.09.2024 / 15:00 CET/CEST The issuer is solely responsible for the content of this announcement. PRE...
EQS-News: Biotest AG opens 13th plasma collection center in Germany
EQS-News: Biotest AG / Key word(s): Miscellaneous Biotest AG opens 13th plasma collection center in Germany 05.09.2024 / 09:00 CET/CEST The issuer is solely responsible for the content of this announc...
EQS-News: Dr. Jörg Schüttrumpf resigns from the Management Board of Biotest AG
EQS-News: Biotest AG / Key word(s): Personnel Dr. Jörg Schüttrumpf resigns from the Management Board of Biotest AG 28.08.2024 / 09:00 CET/CEST The issuer is solely responsible for the content of this ...